Alcohol Use Disorder Clinical Trials in New Haven, Connecticut

11 studies are recruiting for alcohol use disorder in New Haven, Connecticut right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Investigating the Mu:Kappa Opioid Receptor Imbalance in Alcohol Use Disorder

   The primary objective of this multimodal positron emission tomography (PET) study is to use PET brain imaging to measure both MOR (Mu-Opioid receptors) and KOR (kappa-opioid receptors) in participants with alcohol use disorder (AUD) and to quantify the relationships between MOR and KOR, separately …

   Stage

   EARLY_Phase 1

   Ages

   21 to 70

   Site

   Yale University, New Haven, Connecticut

   Run by

   Yale University

   See if you can join NCT05957159 on ClinicalTrials.gov

2. Imaging Traumatic Stress and Alcohol Use Disorder With [18F]Bavarostat

   The overall objective of this study it to use Positron Emission Tomography (PET) brain imaging and a radiotracer that measures the epigenetic marker Histone Deacetylase 6 (HDAC6) to examine HDAC6 expression in people with Post-Traumatic Stress Disorder (PTSD), Alcohol Use Disorder (AUD), or concurr…

   Stage

   Not phased

   Ages

   18 to 70

   Site

   Yale University, New Haven, Connecticut

   Run by

   Yale University

   See if you can join NCT06371404 on ClinicalTrials.gov

3. Drinking, Acetate, and Stress

   The purpose of this study is to learn how drinking alcohol affects how people experience stress and how that is affected by the body's chemistry. Specifically, the investigators will be studying relationships of drinking and a stress hormone called cortisol. The investigators believe that results w…

   Stage

   Not phased

   Ages

   18 to 60

   Site

   The Anlyan Center, 300 Cedar St., New Haven, Connecticut

   Locations

   2 in total

   Run by

   Yale University

   See if you can join NCT06584448 on ClinicalTrials.gov

4. Emergency Department-Initiated Medications for Alcohol Use Disorder

   The proposed study will be the first randomized clinical trial to evaluate a comprehensive Emergency Department (ED)-based intervention for moderate to severe Alcohol Use Disorder (AUD) combining Screening, Brief Intervention and Referral to Treatment (SBIRT) with ED-initiated medications for treat…

   Stage

   Phase 3

   Ages

   18 to 80

   Site

   Yale New Haven Hospital, New Haven, Connecticut

   Run by

   Yale University

   See if you can join NCT05827159 on ClinicalTrials.gov

5. Phase 2 Study of Apremilast in Women and Men With Alcohol Use Disorder

   For this protocol, the investigators plan to collect data to evaluate apremilast (60mg/day) vs placebo in adults with Alcohol Use Disorders (AUD).

   Stage

   Phase 2

   Ages

   21 to 65

   Site

   Yale University, New Haven, Connecticut

   Run by

   Yale University

   See if you can join NCT07029529 on ClinicalTrials.gov

6. Developing a Novel Human Laboratory Paradigm for AUD Medication Screening

   The intent of the study is to develop two versions of the 'ability to resist' drinking model designed to screen Alcohol Use Disorder (AUD) medications.

   Stage

   Not phased

   Ages

   21 to 65

   Site

   Yale University, New Haven, Connecticut

   Run by

   Yale University

   See if you can join NCT06489782 on ClinicalTrials.gov

7. Implementation Facilitation Pilot for Alcohol Use Disorder (AUD) in Alcohol-associated Liver Disease (ALD)

   The goal of this project is to improve provision of integrated medications for alcohol use disorder (MAUD) with brief counseling for patients with alcohol use disorder (AUD) and alcohol-associated liver disease (ALD) in hepatology clinics. There are many benefits of AUD treatment among patients wit…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Yale School of Medicine/Yale-New Haven Health, New Haven, Connecticut

   Run by

   Yale University

   See if you can join NCT07525258 on ClinicalTrials.gov

8. Study of NTX-2001 on Alcohol Consumption in Alcohol Use Disorder

   The primary goal of this Phase 1b clinical trial is to evaluate the effects of a novel TAAR1 receptor partial agonist (NTX-2001) in adults with Alcohol Use Disorder (AUD). The main questions this trial aims to answer are: * Does NTX-2001 affect alcohol consumption in adults with AUD? * Is NTX-2001 …

   Stage

   Phase 1

   Ages

   21 to 60

   Site

   Yale University School of Medicine, Connecticut Mental Health Center, New Haven, Connecticut

   Run by

   Newleos Therapeutics, Inc.

   See if you can join NCT07520292 on ClinicalTrials.gov

9. A First in Human Study of CMND-100 in Healthy and Alcohol Use Disorder (AUD) Subjects

   The primary objective of this study is to find the tolerable dose and characterize the safety and pharmacokinetics/ pharmacodynamics (PK/PD) of single and repeated dose of CMND-100 in Healthy Volunteers (HV) and Subjects with Alcohol Use Disorder (AUD). The secondary objective of this study is to p…

   Stage

   Phase 1

   Ages

   18 to 60

   Site

   Connecticut Mental Health Center, New Haven, Connecticut

   Locations

   4 in total

   Run by

   Clearmind Medicine Inc.

   See if you can join NCT05913752 on ClinicalTrials.gov

10. Pregnenolone for the Treatment of Alcohol Use Disorder

    This Phase 2 randomized cotrolled trial (RCT) will assess the safety and efficacy of pregnenolone (PREG; 300 mg/day, b.i.d dosing) vs. placebo (PBO) over a 12 week treatment period, and at 1-month post-treatment follow-up in individuals with Alcohol Use Disorder (AUD).

    Stage

    Phase 2

    Ages

    18 to 70

    Site

    The Yale Stress Center: Yale University, New Haven, Connecticut

    Run by

    Yale University

    See if you can join NCT05781009 on ClinicalTrials.gov

11. TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk

    Ecological momentary interventions (EMI), which use phones to deliver messages to reduce alcohol use and related risk behaviors during or prior to drinking events, can help to address triggers in real-time. GPS tracking can determine when individuals visit places they have previously reported drink…

    Stage

    Not phased

    Ages

    18 to 35

    Site

    Yale University, New Haven, Connecticut

    Locations

    2 in total

    Run by

    University of Kentucky

    See if you can join NCT05576350 on ClinicalTrials.gov